Adenium Biotech

Founded in 2011 as a spin-off from Novozymes A/S, Adenium Biotech is a Danish biopharmaceutical company dedicated to the development and commercialization of innovative antibiotics aimed at treating multi-drug-resistant bacterial infections. Our primary focus is on addressing nosocomial infections, particularly complicated urinary tract infections (UTIs) and hospital or ventilator-acquired pneumonia (VAP), caused by multi-drug-resistant Gram-negative bacteria.

Complicated UTIs are often triggered by Gram-negative bacteria, especially Escherichia coli (E. coli). While many E. coli infections can be treated easily, hospital-adapted strains are frequently multi-resistant, posing serious health risks. Similarly, hospital-acquired pneumonia and ventilator-associated pneumonia are major concerns due to pathogens like Pseudomonas aeruginosa and Klebsiella pneumoniae. These bacteria are particularly challenging to treat because of their resistance to multiple antibiotics, especially in patients with weakened immune systems.

Although Acinetobacter infections are less common outside hospital settings, they represent a significant threat to critically ill patients. Strains such as Acinetobacter baumannii are highly resistant to antibiotics and can cause severe infections, including pneumonia, bacteremia, wound infections, and UTIs. Adenium Biotech is committed to finding novel solutions to combat these multi-resistant bacterial infections.

One of our key projects is Arenicin, a non-hemolytic and non-cytotoxic antimicrobial peptide derived from the lugworm. Arenicin shows strong efficacy against Gram-negative bacteria and has a broad therapeutic window. After rigorous testing and evaluation, three Arenicin variants were selected in December 2013 for further development, bringing us closer to introducing a new lead product candidate.

Adenium Biotech operates with a lean, expert team and is supported by an international scientific advisory board. Our semi-virtual model allows us to efficiently advance the Arenicin program from clinical development through to regulatory approval.

Paul Goldenheim

Dr. Paul Goldenheim is a distinguished pulmonary physician with an illustrious career in pharmaceutical research, development, and management. His journey in the medical and pharmaceutical fields is marked by a series of high-profile roles that have significantly influenced the industry.

Paul Goldenheim’s career began with a solid academic foundation. He graduated magna cum laude with highest honors in biochemical sciences from Harvard College, where he demonstrated his exceptional intellect and dedication to scientific excellence. He further honed his expertise by earning his MD from Harvard Medical School, one of the world’s most prestigious medical institutions.

Dr. Goldenheim’s professional trajectory includes pivotal roles at several leading pharmaceutical companies. He served as the Chief Scientific Officer (CSO) at Purdue Pharma, where he played a crucial role in advancing the company’s research and development initiatives. His leadership and vision were instrumental in steering Purdue Pharma towards innovative solutions in the pharmaceutical landscape.

As President of TransForm Pharmaceuticals, Dr. Goldenheim led the company to new heights before its acquisition by Johnson & Johnson. His strategic direction and management prowess were key factors in the company’s success and its eventual integration into one of the largest healthcare conglomerates in the world.

Dr. Goldenheim also held the position of Vice-Chairman at Hypnion, where his contributions were significant enough to facilitate the company’s acquisition by Eli Lilly. His ability to drive growth and foster innovation was further evidenced during his tenure as Director of Promedior, which was subsequently acquired by Roche, another global leader in the pharmaceutical industry.

Paul Goldenheim
Paul Goldenheim

Transition to Thought Leadership and Blogging

In 2024, Dr. Goldenheim transitioned from his executive roles to share his extensive knowledge through an informative blog. This platform focuses on personal product analysis and first-hand usage reviews, allowing him to reach a broader audience. His blog features detailed reviews and evaluations of pharmaceutical products and medical devices, providing valuable insights based on his vast experience.

Dr. Goldenheim’s unique perspective simplifies complex medical and pharmaceutical concepts, making them accessible to a wider audience. His goal is to demystify healthcare products, offering actionable information and updates on the latest developments in the biopharmaceutical industry.

Through his blog, Dr. Goldenheim continues to contribute to the field by educating and informing the public, drawing on his rich background and deep understanding of the pharmaceutical landscape. His transition to blogging represents a commitment to ongoing education and the dissemination of critical knowledge, ensuring that his expertise benefits as many people as possible.

Author Profile

Avatar
Paul Goldenheim
Dr. Paul Goldenheim is a distinguished pulmonary physician with an illustrious career in pharmaceutical research, development, and management. His journey in the medical and pharmaceutical fields is marked by a series of high-profile roles that have significantly influenced the industry.

Dr. Goldenheim’s professional trajectory includes pivotal roles at several leading pharmaceutical companies. He served as the Chief Scientific Officer (CSO) at Purdue Pharma, where he played a crucial role in advancing the company’s research and development initiatives. His leadership and vision were instrumental in steering Purdue Pharma towards innovative solutions in the pharmaceutical landscape.

Dr. Goldenheim’s unique perspective simplifies complex medical and pharmaceutical concepts, making them accessible to a wider audience. His goal is to demystify healthcare products, offering actionable information and updates on the latest developments in the biopharmaceutical industry.

Through his blog, Dr. Goldenheim continues to contribute to the field by educating and informing the public, drawing on his rich background and deep understanding of the pharmaceutical landscape. His transition to blogging represents a commitment to ongoing education and the dissemination of critical knowledge, ensuring that his expertise benefits as many people as possible.
Latest entries